Bachem and Axon Neuroscience sign finished dosage form contract

Axon product targets Alzheimer’s disease

Bachem is to manufacture an investigational API for Slovakian biotechnology firm Axon Neuroscience and supply it as a finished dosage form under Bachem’s Clinalfa brand. Axon’s product, which targets Alzheimer’s disease, consists of a peptide-protein conjugate and will enter Phase I clinical trials in Europe.

Roman Sivak, CEO of Axon Neuroscience, said: ‘We have chosen Bachem because of its stellar reputation for quality work and the wide range of services it provides, spanning peptide API production to conjugates and fill finish activities.’

Bachem, headquartered in Bubendorf, Switzerland, specialises in the process development and the manufacturing of peptides and complex organic molecules as active pharmaceutical ingredients (APIs), as well as innovative biochemicals for research purposes.

Companies